Issue 9, 2021

The design of cyclometalated iridium(iii)–metformin complexes for hypoxic cancer treatment

Abstract

Modulating the hypoxic microenvironment is the priority for tumor treatment. Cytometalated iridium(III)–metformin conjugates were synthesized for treating hypoxic cancer cells for the first time, which alleviate hypoxia via mitochondria respiration inhibition, thus displaying 10-fold higher cytotoxicity, emerging anti-metastasis and anti-inflammatory activities than a metformin-free Ir(III) complex and cisplatin against hypoxic cancer cells.

Graphical abstract: The design of cyclometalated iridium(iii)–metformin complexes for hypoxic cancer treatment

Supplementary files

Article information

Article type
Communication
Submitted
27 Oct 2020
Accepted
04 Jan 2021
First published
05 Jan 2021

Chem. Commun., 2021,57, 1093-1096

The design of cyclometalated iridium(III)–metformin complexes for hypoxic cancer treatment

J. Yang, H. Fang, Q. Cao and Z. Mao, Chem. Commun., 2021, 57, 1093 DOI: 10.1039/D0CC07104H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements